Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Oncotherapy On Track For Japan’s First Cancer Vaccine

This article was originally published in PharmAsia News

Executive Summary

Japan's Oncotherapy Science reports favorable late-phase trials on a vaccine for treating pancreatic cancer. The company said preliminary data from Phase II and III trials increase the chances for marketing approval of what would be Japan's first cancer vaccine by the end of next year. The compound being tested is OTS102, which relies on preventing formation of blood vessels in the area of a tumor. Fuso Pharmaceutical Industries has domestic marketing rights for the vaccine. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts